Back HCV Treatment Experimental HCV Drugs TAG Offers New Guide to Clinical Trials for People with Hepatitis C

TAG Offers New Guide to Clinical Trials for People with Hepatitis C

alt

The Treatment Action Group (TAG) has produced a new booklet for people considering taking part in clinical trials for new therapies for hepatitis C.

The advent of direct-acting antivirals for hepatitis C virus (HCV) infection -- starting with the approval of boceprevir (Victrelis) and telaprevir (Incivek) earlier this year -- is revolutionizing the treatment of chronic hepatitis C. These HCV protease inhibitors currently must be used with pegylated interferon plus ribavirin, but several all-oral, interferon-sparing regimens are under study.

Written by Tracy Swan and Matt Sharp, the new Guide to Clinical Trials for People with Hepatitis Cis a unique resource to help people make informed choices about their healthcare, according to TAG. It combines an overview of the drug development process, including phases and types of trials, along with specific information about HCV treatment, adherence, drug resistance, side effects, and new drugs and strategies.

The guide can be downloaded free in PDF format in English and Spanish:

Guide to Clinical Trials for People with Hepatitis C - http://treatmentactiongroup.org/uploadedFiles/About/Publications/TAG_Publications/Publications_by_Topic/HCVClinicalTrialsGuide.pdf

Guía sobre ensayos clínicos para personas con hepatitis C - http://treatmentactiongroup.org/uploadedFiles/About/Publications/TAG_Publications/Publications_by_Topic/HCVClinicalTrialsGuideSPANISH.pdf

8/16/11

Reference

Treatment Action Group (www.treatmentactiongroup.org). August 2011.